Scanning electron microscopy of retained extracellular vesicles on the filter membrane.

Platform Enhances Purity and Reproducibility of Extracellular Vesicle Proteomics

Low-cost, high-throughput method improves purity and reproducibility of EV-based proteomics

Ghent, 07 July 2025 – A group of researchers at the VIB-UGent Center for Medical Biotechnology has developed a new platform to isolate and analyse extracellular vesicles (EVs), nanosized particles secreted by cells and playing a role in cellular communication and disease development. Called FAEVEr, the method increases the throughput of EV enrichment and is significantly more cost-efficient than existing methods. The study was published in the Journal of Extracellular Vesicles.

Extracellular Vesicles (EVs) are small particles that carry proteins, RNA, and other biomolecules from their cell of origin. They hold much promise for diagnostics and therapeutics, but isolating them from complex biofluids at high purity and throughput remains a major challenge. EVs are incredibly small - between 30 and 150 nanometers in size. To capture these tiny containers of messengers, scientists need to rely on sophisticated equipment such as ultracentrifuges. Unfortunately, these traditional methods of EV enrichment are time-consuming and resource-intensive with relatively low throughput.

Now, researchers in the lab of Prof. Kris Gevaert at the VIB-UGent Center for Medical Biotechnology have developed a novel EV-enrichment method. Building on their earlier work published in Molecular & Cellular Proteomics (January 2025), they demonstrated the effectiveness of Filter-Aided Extracellular Vesicle Enrichment, or FAEVEr in enriching EVs from individual samples in a miniaturized and 96-well high-throughput format.

Transmission electron microscopy reveals intact EVs with their distinct morphology and low background after their enrichment and purification using FAEVEr including 5% Tween-20 (size bar of 100 nm).

Cost-efficient and fast

The new platform promises a much faster and more affordable alternative to existing EV-enrichment methods. Using 96-well filter plates, FAEVEr enables a much higher throughput volume by parallel processing of samples in under 2 hours.

Essential to the FAEVEr method is the use of Tween-20, a mild and inexpensive detergent added during EV washing steps. Its inclusion proved critical for improving the purity of the EV proteome by preventing fouling of the filter membranes used to trap EVs and by breaking weak interactions between EVs and contaminating abundant proteins. Importantly, this improvement in purity does not require complex chemistry or costly reagents, making the method accessible for both labs and clinical research settings using standard lab equipment.

Dr. Jarne Pauwels, first author of the study: “We noticed that the addition of higher concentrations of Tween-20 led to a marked reduction in contaminating non-EV proteins and a significant increase in the identification of transmembrane proteins, a key metric in our studies.”
Schematic overview of the streamlined, high-throughput FAEVEr approach for characterization and proteome analysis.

Doing clinicians a FAEVEr

This innovation paves the way for more reproducible EV-based proteomics and strengthens the foundation for future clinical applications of EVs in diagnostics.

“We hope this new approach can find its way into clinical practice”, adds Prof. Kris Gevaert, Director of the VIB-UGent Center for Medical Biotechnology. “FAEVEr lowers the barrier for EV enrichment and offers a significantly faster and much more cost-efficient approach to analyzing plasma or urine biopsies for biomarkers. We hope this new technology can contribute to faster diagnoses for patients.”

The method is already being applied in collaborations focused on prostate cancer, where enriched EV analysis may help identify disease-specific protein signatures from a simple urine sample.


Publication

Pauwels et al. “A 96well ultrafiltration approach for the high-throughput proteome analysis of extracellular vesicles isolated from conditioned medium” Journal of Extracellular Vesicles, 2025.

Funding

The research team at the VIB-UGent Center for Medical Biotechnology was financially supported by FWO, the Ghent University Concerted Research Actions and the interuniversity BOF program.


Joran Lauwers

Joran Lauwers

Press Contact, VIB

About the VIB-UGent Center for Medical Biotechnology

Research at the VIB-UGent Center for Medical Biotechnology can lead to more effective medicine. If we know the causes and mechanisms of a disease, we can then deal with it in a better way. This is much more efficient than treating the symptoms, which is how things are often done at the moment. The research helps to prevent, diagnose or treat diseases.

Share

Latest stories

Website preview
Researchers identify a key biological tipping point in Alzheimer’s disease
Leuven, 4 June 2026 – Researchers from VIB, KU Leuven, the UK-DRI and Muna Therapeutics, funded by, among others, ERC, have uncovered a critical biological transition that may determine whether Alzheimer’s disease pathology leads to dementia. Studying brain tissue from older adults with and without cognitive decline, as well as cognitively healthy centenarians, the team identified distinct cellular programs and immune-cell states associated with disease progression and resilience. Their findings, published in Nature Medicine, suggest that changes in microglia—the brain’s resident immune cells—could represent an important target for future Alzheimer’s therapies.
press.vib.be
Website preview
Prof. Diether Lambrechts (KU Leuven/VIB) receives the Francqui-Collen Prize 2026
Brussels, June 2, 2026 – Prof. Dr. Diether Lambrechts (KU Leuven/VIB) and Prof. Dr. Patrice Cani (UCLouvain) are the laureates of the Francqui-Collen Prize 2026, one of the highest scientific distinctions in Belgium. Today, they receive the award from the hands of King Philippe. Prof. Lambrechts is being honored for his groundbreaking genetic research into cancer treatments, while Prof. Cani is recognized for his discoveries regarding the impact of gut bacteria on lifestyle-related diseases.
press.vib.be
Website preview
Comprehensive atlas maps dendritic cells across cancers
Brussels, 01 June 2026 — Researchers from VIB, VUB, and an international network of collaborators have created the most comprehensive single-cell atlas to date of tumor-associated dendritic cells. By integrating data from 14 mouse tumor models and 10 human cancer types, the study provides a detailed, cross-species view of how these key immune cells are organized and altered in cancer. This work, which appeared in Nature Communications, can guide the development of next-generation therapies.
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be